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Abstract
Purpose The purposes of this study were to assess the impor-
tance of perceived sodium reduction barriers among patients
with chronic kidney disease (CKD) and identify associated
sociodemographic, clinical, and psychosocial factors.
Method A total of 156 patients with CKD completed a ques-
tionnaire assessing sodium reduction barriers (18 self-
formulated items), depressive symptoms (Beck Depression
Inventory), perceived autonomy support (Modified Health
Care Climate Questionnaire), and self-efficacy (Partners in
Health Questionnaire). Factor analysis was used to identify
barrier domains. Correlation coefficients were computed to
examine relationships between barrier domains and patient
characteristics.
Results Nine barrier domains were identified. Barriers per-
ceived as important were as follows: high sodium content in
products, lack of sodium feedback, lack of goal setting and
discussing strategies for sodium reduction, and not experienc-
ing CKD-related symptoms (mean scores > 3.0 on 5-point
scales, ranging from 1 ‘no barrier’ to 5 ‘very important barrier’).
Other barriers (knowledge, attitude, coping skills when eating
out, and professional support) were rated as moderately impor-
tant (rated around midpoint), and the barrier ‘intrinsic motiva-
tion’ was rated as somewhat important (mean score = 1.9).
Sodium reduction barrier domains were not associated with
gender and kidney function, but were associated with age, level
of education, number of comorbidities, perceived autonomy
support, depressive symptoms, and self-efficacy (range
r = 0.17–0.35). Patients with lower self-efficacy and perceived
autonomy support scores experienced most sodium reduction
barriers.
Conclusion Patients with CKD experience multiple important
sodium reduction barriers and could benefit from support
strategies that target various sodium reduction barriers and
strengthen beliefs regarding self-efficacy and autonomy sup-
port. Additionally, environmental interventions should be im-
plemented to reduce sodium levels in processed foods.
Keywords Chronic kidney disease (CKD) . Lifestyle
adherence . Patient-centered care . Perceived barriers .
Reducing sodium intake . Self-management interventions
Introduction
In patients with chronic kidney disease (CKD), kidney func-
tion gradually and usually permanently declines over time.
The severity of CKD can be classified into five stages, with
CKD stage 5 as most advanced stage of CKD. In CKD stage
5, many patients progress towards end stage kidney disease
(ESKD) in which kidney replacement therapy (i.e., transplan-
tation or dialysis) becomes necessary to prolong life [1]. In all
stages of CKD, patients are being advised to reduce their
sodium intake to a maximum of 2000 mg a day [2] because
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a reduction to the recommended amount of sodium has been
associated with beneficial health outcomes, for example a de-
creased blood pressure [3–5]. In early stages of CKD, limiting
sodium intake is considered especially important because it
can contribute to slowing down disease progression towards
ESKD and to reduce risks of cardiovascular complications [6,
7]. Unfortunately, daily sodium consumption of most patients
with CKD far exceeds the advised sodium intake [5], and it
seems that current health care does not provide patients with
the necessary support to incorporate the sodium treatment
guidelines into their daily life.
Literature suggests that in order to successfully limit die-
tary sodium in patients with CKD, behavioral support strate-
gies are needed [3, 5]. It has also been argued that individual-
ization of support is vital, for instance by taking patients’
perceived barriers into account [8, 9]. However, to the best
of our knowledge, there is a paucity of data on barriers regard-
ing a low-sodium diet in patients with CKD, and the studies
that have been conducted were performed in patients with
ESKD (more specifically, in patients receiving hemodialysis)
[10–12]. Moreover, these studies focused on only a few sodi-
um barriers; Clark-Cutaia et al. assessed the importance of
three sodium barrier items (‘Sometimes I crave salty foods’,
‘Resisting salty foods where I work is difficult for me’, and ‘I
have trouble keeping track of the amount of the nutrients that I
eat from meal to meal (such as sodium, potassium, phospho-
rus)’ [13]) [10], and Agondi et al. andWelch et al. assessed the
importance of five sodium barrier items (i.e., ‘Eating a low salt
diet makes it difficult to eat out’, ‘The food does not taste good
in a low salt diet’, ‘It is expensive to follow a low salt diet’,
‘Following a low salt diet takes too long’, and ‘It is very
difficult to understand how to follow a low salt diet’) [11, 12].
To increase our understanding of the sodium reduction bar-
riers patients encounter in earlier stages of CKD (i.e., CKD
stage 1 to 4), our study group conducted a qualitative study
(i.e., focus groups with patients and health care professionals)
and the results indicate that patients with CKD experience
multiple barriers when reducing sodium, including a lack of
intrinsic motivation, knowledge, personal goal setting and ac-
tion planning, feedback, coping skills, and support [14]. This
study provided in-depth knowledge about patients’ experi-
ences when reducing sodium, but further research is warranted
to assess how common these identified barriers are in patients
with CKD and to examine which barriers patients perceive as
most important. Furthermore, the qualitative design is not
suitable for assessing which factors are associated with sodi-
um reduction barriers in order to identify patients that will
benefit most from support strategies. Previous studies have
shown that patients with ESKD who received hemodialysis
treatment for a longer time experience more sodium reduction
barriers [11] and that sodium intake is associated with age,
gender, level of education, and comorbidities [10, 11, 15,
16]. Additionally, literature suggests that psychosocial factors,
such as depressive symptoms [17], self-efficacy [18, 19], and
support from health care professionals [18] are associated with
treatment adherence in patients with ESKD, and hence, it is
plausible that these factors are also related to difficulties with
adhering to the sodium treatment guidelines.
Therefore, the objectives of this study were to assess the
importance of previously identified sodium reduction barriers
among patients with CKD stage 1 to 4 and to investigate
whether sociodemographic, clinical, and psychosocial factors
were associated with perceived sodium reduction barriers.
This knowledge will enable us to develop individualized be-
havioral strategies to support patients with CKD in reducing
sodium intake and consequently slow down disease progres-
sion towards ESKD.
Methods
Design and Participants
Participants of this cross-sectional study were recruited be-
tween November 2013 and February 2014 from Leiden
UniversityMedical Centre in the Netherlands. Dutch speaking
patients who were treated for their kidney disease by a ne-
phrologist and with a kidney function (estimated Glomerular
Filtration Rate [eGFR]) of at least 20 ml/min/1.73 m2 (i.e., no
upper limit for eGFR) were eligible for inclusion. Patients in
CKD stage 5 in need for or receiving kidney replacement
therapy or conservative therapy (i.e., palliative care) were ex-
cluded to limit heterogeneity in treatment characteristics that
may influence dietary behavior. Eligible patients received a
study invitation, detailed information explaining the proce-
dure and confidentiality, an informed consent form (for study
participation and medical data collection), a questionnaire,
and a pre-stamped envelope. Participating patients returned
the signed informed consent form and the completed question-
naire. Approval of the medical ethics committee was obtained
(P10.056).
Measurements
After receiving signed informed consent forms, clinical data
was collected from hospital information systems and medical
records. The most recent medical measurements were includ-
ed, given that measurements were conducted within the prior
year. Kidney function was calculated using the abbreviated
Modification of Diet in Renal Disease formula [20]. Sodium
excretion (i.e., a measure for dietary sodium intake) and pro-
tein excretion were estimated from 24-h urinary samples. The
number of comorbidities was computed based on the presents
of diabetes mellitus (type 1 or 2) and cardiovascular disease
(cerebrovascular accident, coronary artery disease, or periph-
eral artery disease).
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The questionnaire comprised items addressing patients’ ex-
periences with sodium reduction and sociodemographic and
psychosocial factors. Prior to usage, the questionnaire was
pilot tested among nine patients and revised based on feed-
back regarding acceptability and feasibility. Sodium reduction
patients were asked whether they had received a sodium ad-
vice from professionals and whether they (had) tried to reduce
their sodium intake. If patients indicated having experience
with reducing sodium (i.e., irrespective of whether they
succeeded), they were invited to fill out items regarding expe-
riences with reducing sodium. The questionnaire also assessed
perceived sodium adherence (single item using Visual
Analogue Scale [VAS], ranging from 1 ‘never’ to 10 ‘always’)
and perceived barriers for reducing sodium intake (using 18
self-formulated items based on a previous qualitative study
[14], rated on a five-point scale ranging from 1 ‘no barrier’
to 5 ‘very important barrier’). A sum score of all sodium
reduction barrier items was computed as indication for the
amount of difficulties experienced. Depressive symptoms
were measured using the Beck Depression Inventory (BDI)
[21]. The BDI contains 21 items using a four-point scale (0–
3), and total scores ranged from 0 to 63, with higher scores
indicating more depressive symptoms. The BDI proved to be
reliable with a Cronbach alpha value of 0.88. Self-efficacy
regarding self-management skills was assessed using the
Partner in Health questionnaire (PIH) [22] and measured the
following domains: knowledge of disease, active participating
in decision-making, ability to monitor and manage symptoms,
adopt a healthy lifestyle, and manage physical, emotional, and
social consequences. A total score was calculated based on the
sum of 13 items rated on a nine-point scale (ranging from 0
‘very bad’ to 8 ‘very good’). The total score ranged from 0 to
104, with a higher score indicating a higher self-efficacy. The
PIH showed good reliability with a Cronbach alpha value of
0.89. Perceived autonomy support from health care
professional was assessed using the Modified Health Care
Climate Questionnaire (HCCQ) [23]. Six items were rated
on a seven-point scale (ranging from 1 ‘fully disagree’ to 7
‘fully agree’). A total score was computed by averaging item
scores, and a higher score implied greater perceived support
from professionals regarding being autonomous. The HCCQ
showed good reliability with a Cronbach alpha value of 0.88.
Analysis
Descriptive statistics were computed for patient characteristics
and sodium reduction barriers. Chi-square tests of association
and t tests were conducted to detect differences in patient
characteristics between patients who were included in and
excluded from analyses.
For the purpose of data reduction, exploratory factor anal-
ysis (EFA) using varimax rotation was conducted to identify
underlying sodium reduction barrier domains. The number
of factors extracted was based on examination of a scree
plot , Kaiser cri terion (eigenvalues > 1), and the
(theoretical) interpretability of the extracted factors.
Furthermore, data was inspected for several standard indi-
ces to assess the factorability and the strength of the rela-
tionship among items, including sample adequacy (e.g.,
Kaiser-Meyer-Olkin measure > 0.50), sphericity (i.e., a sig-
nificant Bartlett’s test [p < 0.05]), common variance (i.e.,
c ommuna l i t i e s > 0 . 5 ) , c o r r e l a t i o n s ( e . g . , n o
multicollinearity), and factor loadings (e.g., minimum item
loading of 0.30, and no or few cross-loadings [i.e., item
loading of 0.32 or higher on two or more factors]) [24,
25]. Subscales were created by averaging items, and inter-
nal consistency was examined using Cronbach’s alpha
measures. Correlation coefficients were calculated to test
associations between sodium reduction barriers (separate
b a r r i e r d oma i n s a n d b a r r i e r s um s c o r e ) a n d
sociodemographic (age, gender, and level of education),
clinical (kidney function and number of comorbidities),
and psychosocial factors (perceived autonomy support, de-
pressive symptoms, and self-efficacy): Pearson correlation
coefficients for continuous factors and point-biserial corre-
lation coefficient for dichotomous factors. To avoid biased
results and loss of power, missing data were imputed using
multiple imputation (using 10 repetitions)—a recommend-
ed technique to deal with missing data in which plausible
estimates are calculated based on known patient character-
istics [26, 27].
Several sensitivity analyses were conducted to test the
robustness of our results. First, analyses were repeated
without imputing missing data. Second, Spearman’s
rank-order correlation coefficients were calculated to in-
vestigate if results would change when treating ‘level of
education’ and ‘number of comorbidities’ (i.e., no comor-
bidity, 1 comorbidity, and 2 comorbidities) as ordinal var-
iables (i.e., 6 education categories ranging from ‘elemen-
tary education’ to ‘higher professional education/universi-
ty’ instead of 2 categories [low and high]). Third, t tests
and one-way analyses of variance (ANOVA Tukey post
hoc) were used to determine if barriers differed between
categories of gender, level of education, and number of
comorbidities. Fourth, p values of correlation coefficients
were corrected for multiple testing using Benjamini and
Hochberg False Discovery Rate [28]. Finally, to investi-
gate if the amount of difficulties patients encounter when
reducing sodium intake is also an indication of adherence
to the sodium treatment guidelines, Pearson correlation
coefficients were calculated for the associations between
the barrier sum score and sodium adherence using objec-
tive (i.e., 24-h urinary sodium excretion) and subjective
(i.e., perceived sodium adherence) measures. All analyses
were performed using SPSS 24.0, and p values of < 0.05
were considered statistically significant.
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Results
Patient Characteristics
The questionnaire was returned by 191 out of 323 patients
(59.1%), after which 35 patients (18.3%) were excluded
from analysis because they had no experience with reducing
sodium intake or because only sociodemographic data was
available (see Fig. 1). No significant differences in patient
characteristics (see Table 1) were detected between patients
who were included in and excluded from the analyses, with
the exception that included patients had lower levels of he-
moglobin (t = −2.3, p = .024), lower kidney function
(t = −2.5, p = .019), and more often cardiovascular disease
(χ2 = 6.3, p = .012). In the included sample of 156 patients,
the mean (SD) sodium excretion was 145.7 (60.1)
mmol/24-h, and patients gave themselves a mean (SD) mark
of 6.6 (2.7) out of 10 on perceived sodium adherence.
Table 1 depicts all patient characteristics.
Perceived Sodium Reduction Barrier Scores
Only four patients (2.6%) indicated that they experience no
barriers when reducing sodium. The results showed that
various sodium reduction barriers could be considered im-
portant (mean scores > 3.0 on a 5-point scale). Patients had
problems managing their low-sodium diet because many
products contain (high levels of) sodium, they did not expe-
rienced CKD-related symptoms, they lack feedback on their
sodium intake, and they did not set personal sodium goals
and discuss strategies on how to reduce sodium with pro-
fessionals. Sodium reduction barriers that were considered
somewhat important were motivation-related barriers
(mean scores ≤ 2.0), indicating that patients did not experi-
ence difficulties because they believe reducing sodium is
not beneficial for them personally or their health. The re-
maining nine barrier items were rated as moderately impor-
tant (mean scores ranging from 2.2 to 2.8). Table 2 contains
scores of all barrier items.
Perceived Sodium Reduction Barrier Domains
The EFA showed a nine factor solution, explaining 81.8% of
the variance. Overall, indicators showed that our data was suit-
able for factor analysis: no multicollinearity was detected,
Kaiser-Meyer-Olkin exceeded the minimum of 0.50 (val-
ue = 0.63), Bartlett’s test of sphericity was significant
(p = .000), and communalities were greater than 0.50 (mean
value = 0.82). Seven domains with adequate eigenvalues (> 1)
were created that consisted of multiple items with high item
loadings (i.e., ranging from 0.62 to 0.92): attitude (4 items),
professional support (2 items), symptoms (2 items), knowledge
(2 items), intrinsic motivation (2 items), feedback (2 items), and
goal and strategy (2 items). The domains also showedmoderate
to good reliability with Chronbach alpha values ranging from
0.62 to 0.87. The interpretation of the two remaining factors
was less clear with freestanding items assessing the barriers
‘sodium in products’ and ‘coping skills when eating out’, and
with borderline cross-loading detected in the latter barrier (i.e.,
with the domain ‘attitude’). Solutions were examined, but did
not change the results. Due to the nature of this EFA (i.e., data
reduction in light of correlation analysis) and the importance of
both items (mean scores were 2.8 for ‘coping skills when eating
out’ and 3.5 for ‘sodium in products’), the decision wasmade to
treat these single items as separate barrier domains. The barrier
‘sodium in products’, however, was excluded from the correla-
tion analysis because sodium content of products cannot be
modified by patients, and hence, is most likely not associated
with patient characteristics. Table 2 depicts all barrier domains
and Chronbach alpha values.
Factors Associated with Perceived Sodium Reduction
Barrier Domains
The correlation coefficients showed that several
sociodemographic, clinical, and psychosocial factors were asso-
ciated with sodium reduction barrier domains (see Table 3). First,
associations were found between self-efficacy and the barriers
‘knowledge’, ‘attitude’, and ‘feedback’: patients who believed
to a lesser extent that they are capable of managing their disease
Eligible patients that received study invitation (n=323)
Declined study invitation (n=132)
Included in study (n=191)
Excluded: 
- no sodium reduction experience (n=30)
- insufficient data available (n=5)
Included in analysis (n=156)
Fig. 1 Flow diagram of the study
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reported more often that a lack of knowledge was a barrier to
reduce sodium intake (p = .006), expressed a more negative
attitude towards limiting sodium (p = .036), and more often
considered a lack of feedback as a barrier (p = .049).
Associations were also found between age, the number of co-
morbidities, depressive symptoms, and the barrier ‘symptoms’:
older patients, patients with more comorbidities, and patients
with less depressive symptoms more often reported that not
experiencing CKD-related symptoms was a barrier for reducing
sodium (p = .015, p = .027, and p = .007, respectively).
Furthermore, age and level of education were associated with
the barrier ‘goal and strategy’: younger patients and patients with
high levels of education more often considered a lack of setting
goals and planning strategies as a barrier for reducing sodium
(p = .012 and p = .003). The barrier ‘coping skills when eating
out’ was associated with number of comorbidities and self-effi-
cacy: a lack of skills when eating out as barrier for reducing
sodiumwas more often mentioned by patients with more comor-
bidities (p = .035) and by patients who believe to a lesser extent
they are capable to manage their disease (p = .044). Furthermore,
associations were also found between the barrier ‘professional
support’, perceived autonomy support, and self-efficacy: patients
who experienced insufficient professional support as a barrier
believed to a lesser extent that they receive sufficient autonomy
support from professionals and believed to a lesser extent that
they are capable to manage their disease (p < .001 and p = .005).
No factors were associated with the barrier ‘intrinsic motivation’,
and gender and kidney function were not related to barrier do-
mains. Finally, perceived autonomy support and self-efficacy
were associatedwith the barrier sum score: patients who believed
to a lesser extent that they receive sufficient autonomy support
from professionals and patients who believed to a lesser extent
that they are capable to manage their disease, experienced more
barriers when limiting sodium intake (p = .032 and p = .013).
Sensitivity Analysis
The sensitivity analysis showed that the majority of the results
remained stable when conducting complete case analysis,
with the exception that no significant relationships were found
between self-efficacy and the barriers ‘attitude’ and ‘coping
skills when eating out’ (r = −.16 [p = .164] and r = −.19
[p = .097]). However, a significant association was now found
between perceived autonomy support and the barrier ‘coping
skills when eating out’ (r = −.18, p = .041). Furthermore,
compared to the main analysis, similar results were found
when calculating Spearman’s rank-order correlation coeffi-
cients for associations between sodium reduction barriers, lev-
el of education, and number of comorbidities on an ordinal
level (data not shown). The t tests revealed that patients with
high levels of education believed to a higher extent that not
setting goals and discussing strategies are important barriers
compared to patients with low levels of education (mean [SD]
Table 1 Patient characteristics (n = 156)
Characteristic
Sociodemographic
Age, years, mean ± SD 62.1 ± 13.6
Sex, male, N (%) 93 (59.6)
Ethnicity, Dutch, N (%)* 139 (89.1)
Married or cohabiting, yes, N (%) 118 (75.6)
Education, low, N (%)**,a 86 (55.1)
Paid work status, yes, N (%)*** 53 (34.0)
Clinical b
Primary cause of renal failure, N (%)□,c
Diabetes mellitus 5 (3.2)
Glomerulonephritis 44 (28.2)
Renal vascular disease 16 (10.3)
Other cause 79 (50.6)
Diabetes mellitus, N (%)□ 27 (17.3)
Cardiovascular disease, N (%)□ 50 (32.1)
Time on nephrology care, years, median (IQR)□□ 4 (1–13)
Systolic blood pressure, mm Hg, mean ± SD□□□ 134 ± 19
Diastolic blood pressure, mm Hg, mean ± SD□□□ 79 ± 11
Use of antihypertensive medication, yes, N (%)Δ 123 (78.8)
Body mass index, kg/m2, mean ± SDΔΔ 27.1 ± 4.4
Hemoglobin, g/dL, mean ± SDΔΔΔ 13.5 ± 1.6
eGFR, mL/min/1.73 m2, mean ± SD† 47.6 ± 21.5
Protein excretion, g/24-h, median (IQR)‡ 0.3 (0.1–0.9)
Sodiumb
Sodium, mmol/24-h, mean ± SD‡,d 145.7 ± 60.1
Perceived sodium adherence, mean ± SDϕ 6.6 ± 2.7
Received sodium advice from professional, yes, N (%) 67 (42.9)
Psychosocial
Perceived autonomy support, mean ± SDϕϕ 5.8 ± 0.8
Self-efficacy, mean ± SDϕϕϕ 73.7 ± 17.5
Depressive symptoms, mean ± SD⋄ 7.3 ± 6.4
Continuous variables are presented asmean ± SD for normally distributed
variables andas median (IQR) for skewed variables
Available for: * 155 (99.4%), ** 154 (98.7%), *** 153 (98.1%), □ 144
(92.3%), □□ 140 (89.7%), □□□ 143 (91.7%), Δ 127 (81.4%), ΔΔ 111
(71.2%), ΔΔΔ 115 (73.7%), † 114 (73.1%), ‡ 78 (50.0%), ϕ 144 (92.3%),
ϕϕ 141 (90.4%), ϕϕϕ 86 (55.1%), ⋄ 138 (88.5%) patients
a Low education was classified as primary education and lower secondary
education
bDifferences in time between completing the questionnaire and clinical
measurements/mean (SD) of 0.5 (2.5) months for eGFR, mean (SD) of
1.7 (3.3) months for sodium excretion, mean (SD) of 1.6 (3.7) months for
protein excretion, mean (SD) of 0.7 (0.9) for hemoglobin, median (IQR)
of 3.6 (0.4–9.9) months for body mass index, and median (IQR) of 0.2
(−1.3–3.3) months for blood pressure measurements
c Primary kidney disease was classified into four categories following the
European Renal Association-Dialysis and Transplantation Association
registry codes [29]
d Conversion factor for mmol/24-h sodium excretion to mg/24-h sodium
excretion: ×23
Int.J. Behav. Med. (2018) 25:93–102 97
of 3.7 [0.8] compared to 3.2 [1.0], p = .003) and revealed
that none of the barriers differed between men and women
(data not shown). The ANOVAs showed that there was an
association between the number of comorbidities and the
barrier ‘symptoms’ (F = 4.1 [2, 154], p = .017), and post
hoc comparison indicated that patients with two comorbid-
ities believed to a higher extent that not experiencing CKD-
related symptoms is an important barrier compared to pa-
tients with no comorbidities (mean [SD] was 3.8 [1.0] com-
pared to 2.7 [1.2], p = .013). Furthermore, after correction
for multiple testing, two associations remained significant:
level of education was associated with the barrier ‘goal and
strategy’ (p = .036), and perceived autonomy support was
associated with the barrier ‘professional support’ (p < .001).
Only trends were now observed for associations between
self-efficacy and the barriers ‘knowledge’ (p = .060), and
‘professional support’ (p = .055), and between depressive
symptoms and the barrier ‘symptoms’ (p = .065). Finally,
the analyses showed that the barrier sum score was associ-
ated with perceived sodium adherence (r = −0.53, p < .001,
n = 109), but not with 24-h urinary sodium excretion
(r = 0.03, p = .811, n = 60).
Table 2 Descriptives of sodium
reduction barrier items, domains,
sum score, and Chronbach alpha
values (n = 156)
Sodium reduction barriers Mean (SD)
Attitude (α = 0.63)□ 2.5 (0.8)
Low-sodium food taste bad 2.7 (1.2)
A low-sodium diet is unsocial 2.4 (1.1)
A low-sodium diet is time and energy consuming 2.3 (1.1)
Low-sodium products are expensive 2.6 (1.2)
Symptoms (α = 0.86)□□ 3.2 (1.2)
Not feeling ill 3.3 (1.2)
No CKD-related symptoms 3.0 (1.2)
Professional support (α = 0.87)□□□ 2.5 (0.9)
Health care professionals are not patient-centered enough 2.4 (0.9)
Health care professionals have insufficient time to support me 2.6 (0.9)
Knowledge (α = 0.75)Δ 2.3 (0.9)
Insufficient knowledge on how to reduce sodium intake 2.2 (1.0)
Insufficient knowledge about sodium content in products 2.4 (1.0)
Intrinsic motivation (α = 0.83)□□ 1.9 (0.8)
A low-sodium diet is not beneficial for my health 1.9 (0.9)
A low-sodium diet is not important for me personally 2.0 (0.8)
Feedback (α = 0.70)ΔΔ 3.1 (1.1)
Insufficient insight into my daily sodium intake 3.3 (1.2)
Receiving insufficient feedback on my sodium intake 3.0 (1.2)
Goal and strategy (α = 0.62)ΔΔ 3.4 (1.0)
No personal and concrete goals have been set to reduce my sodium intake 3.1 (1.2)
No sodium reduction strategies have been discussed with my professional 3.7 (1.1)
Coping skills when eating outΔΔΔ
Difficult to refuse food at parties and when eating out 2.8 (1.2)
Sodium in products□□□
The majority of products contain (high levels of) sodium 3.5 (1.2)
Barriers sum score (α = 0.79)a 49.5 (9.2)
Data available between 135 (86.5%) and 147 (94.2%) patients for each single barrier
Loadings were strong for primary items in the domains ‘attitude’ (0.88, 0.78, 0.62, and 0.86, respectively),
‘symptoms’ (0.91 and 0.91), ‘professional support’ (0.90 and 0.92), ‘knowledge’ (0.83 and 0.90), ‘intrinsic
motivation’ (0.91 and 0.88), ‘feedback’ (0.76 and 0.84), ‘goal and strategy’ (0.84 and 0.87), ‘coping skills when
eating out’ (0.53), and ‘sodium in products’ (0.82)—all other item loadings on the factors were well below 0.40
Data of domains available for the following: □ 143 (91.7%), □□ 139 (89.1%), □□□ 129 (82.7%), Δ 137 (87.8%),
ΔΔ 141 (90.4%), ΔΔΔ 135 (86.5%). Possible range is 1–5, with 1 indicating ‘no barrier’ and 5 ‘very important
barrier’
a Barrier sum score was calculated when all barrier data were available (n = 111, 71.2%). Possible score range is
18–90, with higher scores indicating more difficulties with reducing sodium intake
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Discussion
This study has shown, in accordance with previous studies
[10–12, 14, 30], that patients with CKD perceive adhering to
a low-sodium diet as a difficult task. They regard multiple
barriers to be important when reducing sodium: patients be-
lieved to a high extent that reducing sodium is difficult be-
cause many products contain (high levels of) sodium, they do
not experience CKD-related symptoms, lack feedback on so-
dium intake, and do not set sodium goals and discuss strate-
gies for reducing sodium with professionals. Patients also be-
lieved to a moderate extent that reducing sodium is difficult
because they have insufficient knowledge on how to reduce
sodium intake, lack the skills to refuse food when eating out,
receive insufficient support from professionals, and perceive a
low-sodium diet as untasteful, unsocial, expensive, and time
and energy-consuming. Finally, most patients did not experi-
ence difficulties because they believe that reducing sodium
intake is not beneficial for them personally or for their health.
Direct comparison with literature is difficult because previous
studies assessed the importance of only a few sodium reduc-
tion barriers in patients with ESKD (more specifically, in pa-
tients receiving hemodialysis) [10–12]. However, barrier
items included by Agondi et al. and Welch et al. partially
overlap with items of our domains ‘attitude’, ‘knowledge’,
and ‘coping skills when eating out’ [11, 12]. Comparison of
mean scores on these items suggests that in all three studies,
many patients believed to a moderate extent that reducing
sodium is difficult because it is time-consuming and expen-
sive, and they lack knowledge on how to reduce sodium (i.e.,
items rated around midpoint). However, patients in our study
believed to a lesser extent that a bad taste of low-sodium food
makes it difficult to adhere to a low-sodium diet (2.7 versus
3.8 and 3.3) [11, 12] and they reported less problems with
adherence when eating out (2.8 versus 3.7) [11]. Although
all studies specifically address sodium barriers, higher scores
in previous studies could be explained by the patient popula-
tion: patients receiving hemodialysis have additional diet re-
strictions (e.g., protein and potassium restrictions), and hence,
restrict patients even more in choosing and cooking healthy
but also tasty food. Finally, previous studies did not assess
barriers related to motivation; however, they did assess patient
beliefs about benefits of a low-sodium diet [11, 12]. They
found that patients with ESKD believed to a high extent that
a low-sodium diet is good for their health, which corresponds
with our finding that patients do not experience difficulties
because they think it is not beneficial for their health.
We also identified patient characteristics that were related
to barriers for adhering to a low-sodium diet. Various sodium
reduction barriers (i.e., a negative ‘attitude’, and a lack of
‘knowledge’, ‘symptoms’, ‘goal setting and discussing strate-
gies’, ‘feedback’, ‘coping skills when eating out’, and ‘profes-
sional support’) were associated with patient characteristics,
namely age, level of education, depressive symptoms, number
of comorbidities, perceived autonomy support, and self-effi-
cacy. Furthermore, patients who believed to a lesser extent that
they are capable to manage their disease and patients who
believed to a lesser extent they receive sufficient autonomy
support from professionals, experienced more barriers when
limiting dietary sodium. These findings suggest that patients
differ in the extent to which they experience barriers when
striving to adhere to a low-sodium diet. Hereby, this study
adds to previous studies that found these sociodemographic
and clinical factors associated with sodium excretion [10, 11,
15, 16] and found these psychosocial factors associated with
treatment adherence in patients with ESKD [17–19].
Furthermore, the factor that was most consistently related to
sodium reduction barriers was self-efficacy, and these findings
are in line with a previous study by Curtin et al., who found
patients’ self-efficacy, compared to demographic and health-
Table 3 Correlation coefficients for perceived barriers and sociodemographic, clinical, and psychosocial characteristics (n = 156)
Sodium reduction barriers Agea Genderb Level of
education b
Number of
comorbiditiesa
eGFRa Autonomy
supporta
Depressive
symptomsa
Self-
efficacya
Attitude −.06 .17 −.07 .10 −.02 −.01 .08 −.18*
Symptoms .21* −.01 .11 .19* −.16 −.02 −.25** −.09
Professional support −.02 .07 .05 .04 .00 −.35** .09 −.25**
Knowledge −.07 .03 −.04 .08 .04 −.10 .06 −.25**
Intrinsic motivation −.10 −.04 .11 −.18 .12 −.13 −.11 −.06
Feedback −.16 .10 −.01 .11 .00 −.15 .03 −.17*
Goal and strategy −.24* −.03 .25** −.03 .13 −.12 −.06 .11
Coping skills when eating out −.05 .08 −.02 .19* .12 −.14 .09 −.19*
Barriers sum score −.10 .03 .09 .11 .03 −.21* −.06 −.24*
a Pearson correlation coefficients
b Point-biserial correlation coefficients for gender and level of education (categories were low and high level of education)
*P < 0.05, **P < 0.01
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related factors, to be most consistently related to self-
management behavior in patients with CKD [31].
Strengths and Limitations
To the best of our knowledge, this is the first study to assess
the importance of perceived sodium reduction barriers in an
early phase of CKD and to identify which patients could ben-
efit most from support strategies. Other strengths of this study
are that barrier items in the questionnaire were based on a
previous qualitative study [14] and that the questionnaire in-
cluded a broad range of sodium reduction barriers and showed
moderate to good psychometric qualities. However, before
this questionnaire can be used in practice to identify sodium
reduction barriers in individual patients, additional research is
needed (e.g., conducting a confirmative factor analysis in a
larger population or executing a longitudinal study to evaluate
the test-retest reliability).
A limitation of this study is that the date of clinical mea-
surements did not coincide with the date questionnaires were
filled out. However, we do not believe this led to biased results
as the mean (SD) difference between kidney function mea-
surements and completing the questionnaire was 0.5 (2.5)
months and it is expected that kidney function will be constant
in this short period of time. There was also missing data, for
example because patients did not fully complete the question-
naire, patients did not gave permission to collect medical data,
or clinical measurements were not conducted within the prior
year. However, the majority of the results prior and after im-
putations were similar and few differences were detected be-
tween patients who were included in and excluded from anal-
yses, and therefore, it is unlikely that missing data led to bi-
ased results. Furthermore, the sensitivity analysis showed that
the barrier sum score was associated with perceived sodium
adherence, but not with 24-h urinary sodium excretion.
Explanations for these findings could be that limited data on
sodium excretion was available (50%), and that we used a
single sodium measurement [9] that was measured on a date
that do not coincide with the date questionnaires was filled out
(mean [SD] difference was 1.7 [3.3] months). Finally, al-
though our response rate of 59.1% is similar to the average
response rate of 65% for postal questionnaires in health care
settings [32], it should be noted that our results may not be
fully representative of the broad population of patients with
CKD.
Clinical Implications
The results showed that patients with CKD believed to a rel-
atively high extent that limiting dietary sodium is beneficial,
but still experience multiple barriers when reducing sodium
intake. Therefore, solely educating patients about the benefits
of sodium reduction will be insufficient but a multifaceted
approach that target various important barriers is required to
provide patients with the support they need to incorporate the
sodium treatment guidelines into their daily life. The findings
also suggest that patients who believed to a lesser extent that
they are capable to manage their disease and receive sufficient
autonomy support from professionals, experienced more so-
dium reduction barriers, and thus, support strategies should
also strengthen beliefs regarding self-efficacy and autonomy
support. The need for such a multifactorial approach to sup-
port patients with the complex task of successful behavior
change is in line with literature suggesting that theory-based
self-regulation interventions that encompass multiple behav-
ior change techniques are required [33–36]. Based on our
findings, we believe that in particular, the following strategies
could be of use. First, professionals could use the patient-
centered techniques of motivational interviewing to elicit be-
havior change, increase autonomy support, and strengthen
patients’ self-efficacy [37, 38]. Additionally, it may provide
a solution for the barriers ‘professional support’ and ‘goal and
strategy’, as shared decision making, goal setting, and
discussing action plans are key elements of motivation
interviewing [37]. Second, coaching is considered impor-
tant in behavior change [39], and continuous support and
guidance from professionals could increase self-efficacy
and knowledge of patients. Third, an intervention compris-
ing educational cooking sessions successfully reduced so-
dium intake in patient with CKD [40] and could increase
patients’ practical knowledge and skills on how to reduce
sodium and positively change attitudes (i.e., cooking flavor-
ful dishes that take little time and are inexpensive). Fourth,
self-monitoring has been identified as a key element for
successful behavior change [33, 35], and stimulating pa-
tients to engage in self-monitoring (e.g., sodium intake by
means of an online food diary and home-based blood pres-
sure measurements) could give patients direct feedback on
their sodium intake and disease progression. Fifth, sodium
content of products and eating out were identified as impor-
tant barriers, and hence, environmental interventions should
be implemented as well (e.g., reducing sodium content in
processed and catered foods) [41]. Finally, future studies are
needed to investigate whether the suggested strategies can
indeed help patients to reduce sodium intake and improve
health outcomes in patients with CKD.
Conclusion
Patients with CKD experience multiple important barriers
when reducing sodium intake, especially patients with lower
self-efficacy. Addressing perceived sodium reduction barriers
could be a starting point for interventions to support patients
with CKD in reducing sodium intake and consequently slow
down disease progression towards ESKD.
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